Pharmaceutical Waste Handling and Controlled-Substance Regulations

Federal Standards for Pharmaceutical Waste

The Resource Conservation and Recovery Act (RCRA) is the primary federal law governing the management of solid and hazardous waste in the United States. Enacted in 1976, it establishes requirements covering the waste lifecycle, including generation, transportation, treatment, storage, and disposal. RCRA also provides a framework for managing nonhazardous solid waste.

Identifying Hazardous Pharmaceutical Waste

Under RCRA, hazardous waste is regulated primarily by the Environmental Protection Agency (EPA). A pharmaceutical waste may be hazardous because it appears on an EPA hazardous-waste list or because it demonstrates one or more hazardous-waste characteristics.

The four RCRA hazardous-waste characteristics are:

These RCRA categories should not be confused with the criteria used to classify hazardous drugs for occupational exposure, which may include carcinogenicity, reproductive toxicity, developmental toxicity, genotoxicity, and organ toxicity.

Examples of pharmaceutical or chemical waste that may require special management include certain antineoplastic medications, warfarin-containing products, ignitable formulations, corrosive materials, and other listed or characteristic hazardous wastes. Classification must be based on the specific product and concentration rather than the drug category alone.

Disposal of Hazardous Pharmaceutical Waste

Healthcare facilities and reverse distributors subject to EPA’s hazardous-waste pharmaceutical rules must not dispose of hazardous waste pharmaceuticals into a toilet, sink, or other sewer system. EPA also strongly discourages sewer disposal of pharmaceuticals more generally.

Waste must instead be managed through the appropriate pharmaceutical-waste stream in accordance with:

Waste Container Colors

There is no single federal color-coding system that universally assigns one container color to every category of pharmaceutical waste. Color schemes vary by facility, waste contractor, state requirements, and waste type.

A pharmacy or healthcare facility may use color-coded containers, but staff should follow the labels and procedures established for that facility rather than relying on color alone.

Waste CategoryGeneral Handling Principle
SharpsPlace immediately into an approved puncture-resistant, leak-resistant, closable sharps container.
Biohazardous or infectious wasteUse containers designated by the facility’s infection-control and waste-management procedures.
Trace chemotherapy wasteSegregate according to the facility’s hazardous-drug waste procedures.
RCRA hazardous pharmaceutical wastePlace in a designated hazardous-waste container that meets applicable environmental requirements.
Nonhazardous pharmaceutical wasteUse the facility’s approved pharmaceutical-waste stream rather than regular trash when required by policy.
Radioactive pharmaceutical wasteManage under applicable radiation-safety rules; it should not be grouped with ordinary hazardous pharmaceutical waste solely because of container color.

Key point: The label and waste classification are more important than the container color.

Protecting Workers from Hazardous Drugs

Hazardous drugs may expose pharmacy and healthcare workers through skin or eye contact, inhalation, accidental injection, or contamination of work surfaces. Exposure can occur during tasks such as opening ampules, withdrawing medication from vials, reconstituting powders, transferring solutions, priming IV tubing, cleaning spills, and handling contaminated waste.

Appropriate safeguards may include:

OSHA requires employers to use appropriate engineering controls, work practices, and PPE to protect workers from recognized hazards.

Hazardous drugs should be identified and managed in designated areas according to applicable procedures. Access, labeling, storage, spill response, and waste disposal should reflect the drug’s risk and the facility’s hazardous-drug program.

Safe Sharps Disposal

Used needles, lancets, and other sharps must be placed promptly into suitable sharps containers.

These containers should be:

Needles should not be placed loosely into pharmaceutical-waste containers.

Federal Rules for Controlled-Substance Prescriptions

The Controlled Substances Act (CSA) divides controlled substances into Schedules I through V. Scheduling considers factors including accepted medical use, potential for abuse, and the likelihood of physical or psychological dependence.

Who May Prescribe Controlled Substances

A controlled-substance prescription may be issued by an appropriately authorized practitioner, such as a physician, dentist, veterinarian, podiatrist, or qualifying mid-level practitioner.

The practitioner must be:

Certain practitioners working for registered hospitals or institutions may prescribe under the institution’s DEA registration when federal requirements are satisfied. Therefore, it is not accurate to say that every individual prescriber must always have a separate DEA number.

Schedule II Prescriptions

Refills

Schedule II prescriptions cannot be refilled. A new prescription is required for each additional dispensing.

A prescriber may, when federal and state requirements are met, issue multiple separate Schedule II prescriptions authorizing a total of up to a 90-day supply, with later prescriptions containing instructions such as “Do not fill until” a specified date. These remain separate prescriptions, not refills.

Emergency Oral Schedule II Prescriptions

Schedule II prescriptions are generally written or electronic. An oral Schedule II prescription is permitted only in a qualifying emergency.

In an emergency:

Schedule III and IV Refills

Schedule III and IV prescriptions may be refilled only when authorized.

Under federal law, they may be refilled:

Whichever limit occurs first ends the prescription’s refill authority, and a new prescription is then required.

Schedule V Refills

Federal DEA regulations do not impose the same 5-refill/6-month limitation on Schedule V prescriptions. Refills must be authorized by the prescriber for a legitimate medical purpose and remain subject to state law and other applicable requirements.

Therefore, the statement that Schedule V prescriptions are universally valid for one year is not a federal DEA rule.

Identification at Pickup

Federal DEA law does not establish a universal rule requiring government-issued photo identification for every controlled-substance pickup.

Identification may nevertheless be required by:

Pharmacy personnel should follow the rules applicable to the specific transaction.

Transfers of Controlled Substances

It is important to distinguish transferring prescription information from transferring actual controlled-substance inventory.

Transferring Controlled-Substance Inventory

When Schedule II controlled substances are physically transferred between DEA registrants, the receiving registrant generally must issue a DEA Form 222 or its electronic equivalent to the registrant supplying the drugs.

Transfers of Schedule III–V inventory require appropriate records but do not use DEA Form 222 in the same manner.

Transferring Prescriptions Between Pharmacies

For Schedule III–V refill prescriptions, federal rules generally allow a one-time transfer between DEA-registered pharmacies unless the pharmacies share a real-time online database that permits additional transfers under the regulation. This is one transfer, not “one transfer per day.”

Electronic Controlled-Substance Prescriptions

Since August 28, 2023, a patient may request a one-time electronic transfer for initial filling of an EPCS in Schedules II–V between DEA-registered retail pharmacies when state law permits it. The prescription must remain electronic during the transfer.

For Schedule III–V electronic prescriptions containing refills, the remaining refills can accompany the transferred prescription when applicable.

Reporting Theft or Significant Loss

A DEA registrant that discovers a theft or significant loss of controlled substances must notify its local DEA Diversion Field Office in writing within one business day of discovery.

The registrant must also submit DEA Form 106 documenting the theft or significant loss. Reporting is required even if the drugs are later recovered or the person responsible is identified.

Key Regulatory Distinction

For exam purposes, remember:

When state and federal requirements differ, pharmacy personnel generally must follow the more restrictive applicable requirement.

Controlled-Substance Prescribing, Partial Fills, Transfers, and DEA Requirements

Sequential Schedule II Prescriptions

Schedule II prescriptions cannot be refilled, but federal law allows a prescriber to issue multiple separate prescriptions on the same date for the same Schedule II medication when all legal requirements are met.

A common example is issuing three separate prescriptions for 30-day supplies, for a total of up to 90 days of treatment. Later prescriptions may include instructions such as:

“Do not fill until 10/15/2025.”

The pharmacy may not dispense that prescription before the specified date. The prescriptions are separate orders, not refills of the first prescription.

The dates do not have to be exactly 30 days apart in every case, but the prescriber must clearly indicate the earliest permissible fill date for each future prescription.

Partial Filling of Schedule II Prescriptions

Federal law permits partial filling of Schedule II prescriptions under several circumstances.

When the Pharmacy Cannot Supply the Full Quantity

If the pharmacy does not have enough medication in stock, it may dispense part of the prescription.

Under the traditional federal rule, the remaining quantity must generally be supplied within 72 hours of the partial fill. If the balance cannot be completed within that period, the pharmacist must notify the prescriber, and a new prescription is required for the remaining quantity.

When the Patient or Prescriber Requests a Partial Fill

Under federal law, a Schedule II prescription may also be partially filled at the request of the patient or prescriber when:

The remaining quantity must generally be dispensed within 30 days of the prescription date.

For emergency oral Schedule II prescriptions, the remaining quantity is subject to the shorter emergency-prescription requirements rather than the standard 30-day period.

Partial Fills for Schedule III, IV, and V Prescriptions

Prescriptions for Schedule III, IV, and V controlled substances may be partially filled as long as:

For Schedule III and IV prescriptions, dispensing cannot continue beyond the federal 6-month validity period from the prescription date.

Schedule V prescriptions are not subject to that same federal 6-month limit, although state law may impose stricter restrictions.

Transferring Controlled-Substance Prescriptions

Schedule II Electronic Prescriptions

A valid electronic prescription for a Schedule II controlled substance may be transferred once between DEA-registered retail pharmacies for the purpose of the initial fill, when:

Schedule II prescriptions do not contain refills, so the phrase “along with any authorized refills” does not apply to Schedule II prescriptions.

Schedule III–V Prescriptions

A prescription for a Schedule III, IV, or V controlled substance may generally be transferred one time between pharmacies for refill dispensing.

If both pharmacies electronically share a real-time, online database, the prescription may be transferred back and forth up to the number of remaining authorized refills, subject to state law.

For traditional transfers, the transfer must generally occur directly between licensed pharmacists or otherwise through the electronic process permitted by federal regulation. The transferring pharmacy marks its record as VOID, while the receiving pharmacy records the transferred information.

Controlled-Substance Recordkeeping

DEA registrants must maintain required controlled-substance records for at least 2 years under federal law.

Records for:

State law may require a longer retention period.

Controlled-Substance Inventory Requirements

Initial Inventory

A pharmacy must take an initial inventory of all controlled substances on hand when it first begins handling controlled substances.

The inventory must include a complete and accurate record of controlled substances present at that time.

Biennial Inventory

After the initial inventory, the pharmacy must perform a new inventory at least every 2 years.

The inventory should indicate:

Schedule II substances generally require an exact count or measure. For Schedule III–V substances, estimated counts may be acceptable in some situations, except for larger containers where an exact count is required.

Common DEA Forms Used in Pharmacy Practice

DEA FormPrimary Use
DEA Form 222Ordering or transferring Schedule I and II controlled substances between authorized registrants
DEA Form 224Applying for a new DEA registration as a retail pharmacy, hospital/clinic, practitioner, teaching institution, or mid-level practitioner
DEA Form 224aRenewing certain DEA registrations
DEA Form 41Recording the destruction or surrender of controlled substances in specified circumstances
DEA Form 106Reporting theft or significant loss of controlled substances
DEA Form 104Voluntary surrender of a DEA registration
DEA Form 223Certificate of DEA registration

Important correction: DEA Form 224 is primarily used for a new registration. Renewal is generally handled through Form 224a or DEA’s electronic renewal process.

Comprehensive Addiction and Recovery Act

The Comprehensive Addiction and Recovery Act (CARA) of 2016 expanded federal efforts to address substance use disorders, particularly opioid misuse and overdose.

Major areas supported by CARA include:

CARA also amended federal law to permit patient- or prescriber-requested partial fills of Schedule II prescriptions when applicable conditions are met.

Drug take-back and disposal programs are also part of broader federal controlled-substance disposal policy, although the modern take-back framework also relies on the Secure and Responsible Drug Disposal Act of 2010 and DEA regulations.

Federal Labeling Requirements for Controlled Substances

Commercial containers of controlled substances generally display a symbol identifying the drug schedule.

Examples include:

The symbol must be clearly visible on the commercial label as required by DEA regulations.

Secure Storage of Controlled Substances

Controlled substances must be stored in a manner that provides effective security against theft and diversion.

It is not correct to say that every pharmacy must store all controlled substances only in a steel safe or vault.

Under federal rules:

Access should be limited to authorized personnel, and the pharmacy must maintain security procedures appropriate to its operations.

Federal Safety Programs for Restricted Medications and Product Recalls

Controlled Access and Risk-Reduction Programs

Certain medications and drug products require additional safeguards because they can cause serious harm if used improperly or in high-risk populations. Federal programs such as the Combat Methamphetamine Epidemic Act (CMEA) and Risk Evaluation and Mitigation Strategies (REMS) are designed to reduce these risks.

Combat Methamphetamine Epidemic Act

The Combat Methamphetamine Epidemic Act of 2005 (CMEA) established restrictions on the retail sale of certain scheduled listed chemical products, including products containing pseudoephedrine, ephedrine, and phenylpropanolamine. These substances can be used as precursor chemicals in the illegal manufacture of methamphetamine.

For pseudoephedrine-containing products, federal limits generally include:

Products must generally be kept behind the counter or in a locked cabinet so customers do not have unrestricted access.

For covered retail transactions, the seller must verify the purchaser’s identity using an appropriate government-issued photographic identification and maintain the required sales record or logbook. Required information generally includes the purchaser’s name, address, date and time of sale, product quantity, and the purchaser’s signature. State law may impose stricter limits or additional requirements.

Ryan Haight Act and Internet Prescribing

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 amended the Controlled Substances Act to address improper prescribing and dispensing of controlled substances through the Internet.

Historically, the law generally required a practitioner to conduct at least one in-person medical evaluation before prescribing controlled substances through the Internet unless a statutory telemedicine exception applied.

Current clarification: Temporary federal telemedicine flexibilities have modified how this requirement operates. As of 2026, DEA and HHS have extended certain telemedicine prescribing flexibilities through December 31, 2026, allowing qualifying DEA-registered practitioners to prescribe certain Schedule II–V controlled medications without a prior in-person examination when all applicable federal and state requirements are met.

Therefore, the Ryan Haight Act should not be summarized as requiring an in-person visit in every current telemedicine situation.

Risk Evaluation and Mitigation Strategies

A Risk Evaluation and Mitigation Strategy (REMS) is an FDA-required drug-safety program for certain medications with serious safety concerns. Its purpose is to ensure that the medication’s benefits outweigh its risks.

REMS requirements vary by medication and may include:

Isotretinoin and iPLEDGE

Isotretinoin can cause severe embryo-fetal toxicity and is subject to the iPLEDGE REMS program. The program includes specific requirements for patients, prescribers, and pharmacies to reduce the risk of fetal exposure.

FDA approved modifications to iPLEDGE in February 2026, with implementation delayed until November 15, 2026. The changes include more flexibility for certain pregnancy tests during and after therapy, while pretreatment pregnancy testing remains subject to stricter requirements.

Other REMS Examples

Thalidomide remains an example of a medication requiring substantial risk-management controls because of its severe embryo-fetal toxicity.

Clozapine should no longer be listed as a current REMS medication. FDA removed the Clozapine REMS effective June 13, 2025. Prescribers should still monitor the absolute neutrophil count (ANC) according to the prescribing information, but prescribers, pharmacies, and patients are no longer required to participate in a Clozapine REMS program.

Key REMS Principle

Not every REMS uses the same requirements. For example, negative pregnancy testing may be essential for teratogenic drugs, while other programs may focus on laboratory monitoring, restricted distribution, or prescriber certification.

A recent liver-function test is not a universal REMS requirement and should only be included when required for the specific medication or program.

FDA Drug and Paroduct Recalls

What Is a Recall?

A recall is the removal or correction of a marketed product that FDA considers to violate the laws it administers and against which the agency would otherwise initiate legal action.

Most recalls are voluntarily initiated by the manufacturer or distributor, sometimes after discussion with or at the request of FDA. FDA also has mandatory recall authority for certain categories of regulated products.

Common reasons for medication recalls include:

FDA Recall Classifications

FDA classifies recalls according to the potential health risk associated with use of or exposure to the product.

Recall ClassMeaning
Class IThere is a reasonable probability that use of or exposure to the product will cause serious adverse health consequences or death.
Class IIUse of or exposure to the product may cause temporary or medically reversible adverse health consequences, or the probability of serious harm is remote.
Class IIIUse of or exposure to the product is not likely to cause adverse health consequences, although the product violates FDA requirements.

This is more precise than describing Class II simply as a product that “might cause significant injury.”

FDA Enforcement Reports

FDA publishes information about recalls in its Enforcement Report. The report includes recalls classified as Class I, II, or III, and may also include recalls that have not yet been classified. FDA updates the report as additional information becomes available.

A recall may begin before FDA formally assigns its final classification, so the public warning and the later Enforcement Report classification do not necessarily occur at the same time.

What Happens During a Recall?

FDA and the recalling company may work together to:

Pharmacies should follow recall notices carefully and identify affected products using details such as the NDC, lot number, expiration date, and package configuration.

Example of a Product Safety Recall

In 2023, several ophthalmic products, including certain over-the-counter eye drops, were recalled or the subject of safety warnings because of concerns about microbial contamination and serious eye infections.

Key Federal Pharmacy Laws, Patient Privacy, and Prescription Integrity

Major Federal Drug Laws and Their Impact on Pharmacy Practice

Several federal laws established the modern framework for drug safety, labeling, prescription requirements, and consumer protection in the United States.

Poison Prevention Packaging Act of 1970

The Poison Prevention Packaging Act (PPPA) requires certain household substances, including many prescription medications, to be dispensed in special child-resistant packaging.

Child-resistant packaging is designed to be difficult for children younger than 5 years of age to open while remaining reasonably usable by adults.

A patient or prescriber may request non-child-resistant packaging when permitted. This can be helpful for individuals who have difficulty opening safety containers, such as some older adults or people with impaired hand function.

Pure Food and Drugs Act of 1906

The Pure Food and Drugs Act of 1906 marked the beginning of modern federal food and drug regulation. It prohibited interstate commerce in adulterated or misbranded foods and drugs and established important consumer protections.

The modern FDA developed from the federal regulatory functions created by this law, but the agency was not officially called the Food and Drug Administration until 1930.

Federal Food, Drug, and Cosmetic Act of 1938

The Federal Food, Drug, and Cosmetic Act (FD&C Act) greatly expanded federal drug regulation.

Among its major provisions, it:

Important correction: The 1938 law established the premarket safety requirement. The requirement that manufacturers prove effectiveness was added later by the Kefauver-Harris Amendments of 1962.

Durham-Humphrey Amendment of 1951

The Durham-Humphrey Amendment formally distinguished medications that require professional supervision from those that may be sold over the counter.

It established that drugs that cannot be used safely without a practitioner’s supervision must be dispensed by prescription and bear the appropriate prescription designation.

Kefauver-Harris Drug Amendments of 1962

The Kefauver-Harris Amendments strengthened federal drug regulation following international concern surrounding the thalidomide tragedy.

Thalidomide had been used in several countries for conditions including nausea during pregnancy and was associated with severe fetal abnormalities, particularly limb defects. FDA reviewer Frances Kelsey’s actions helped prevent widespread U.S. marketing of the drug at that time.

The 1962 amendments required manufacturers to establish that new drugs are both:

before receiving marketing approval. They also strengthened requirements for clinical research and drug manufacturing.

Protecting Patient Information Under HIPAA

Understanding HIPAA and PHI

The Health Insurance Portability and Accountability Act (HIPAA) was enacted in 1996. Its Privacy Rule establishes national standards governing the use and disclosure of certain individually identifiable health information.

Protected health information (PHI) is individually identifiable health information created, received, maintained, or transmitted by a HIPAA-covered entity or its business associate.

Examples may include:

A piece of information is PHI when it is linked to health information and the individual can be identified from it.

How Pharmacies Handle PHI

Pharmacies use PHI for activities such as:

Covered pharmacies must use appropriate administrative, physical, and technical safeguards to protect this information from unauthorized access or disclosure.

Patient Access to Health Information

HIPAA generally gives patients the right to inspect or obtain copies of PHI maintained about them in a designated record set.

This right can include paper and electronic records, subject to limited exceptions. If PHI is maintained electronically, patients generally have the right to obtain an electronic copy when it is readily producible in the requested format.

Secure Disposal of PHI

PHI must be disposed of in a way that prevents unauthorized individuals from reading or reconstructing it.

Appropriate disposal methods may include:

Labeled prescription bottles or other PHI may be held in opaque bags within a secure area until collected by an appropriate destruction service. Simply placing PHI in an opaque bag and disposing of it in ordinary accessible trash is not sufficient.

Notice of Privacy Practices

HIPAA-covered healthcare providers with direct treatment relationships must provide patients with a Notice of Privacy Practices (NPP).

The notice explains:

The notice must be made available to patients and prominently posted at the healthcare facility when applicable. Covered entities must also make it available to anyone who requests a copy.

Prescription Record Retention

Record-retention requirements depend on the type of prescription and applicable federal and state law.

For controlled substances, DEA regulations generally require specified records to be maintained for at least 2 years under federal law.

Schedule II controlled-substance records must generally be maintained separately from other records. Schedule III–V records may be kept separately or in a manner that makes them readily retrievable, depending on the record type.

It is not accurate to say that HIPAA or another single federal law requires all pharmacy prescription records to be retained for exactly 2 years. State pharmacy laws may require longer retention periods.

Recognizing Possible Prescription Fraud or Forgery

Pharmacists have a responsibility to identify suspicious controlled-substance prescriptions and avoid knowingly dispensing prescriptions that are forged, altered, or issued outside the usual course of professional practice.

Potential Warning Signs

DEA materials identify possible warning signs such as:

Interestingly, DEA guidance has historically listed unusually legible handwriting and absence of customary abbreviations as possible warning signs in context. These characteristics do not prove forgery on their own. Suspicious prescriptions should be evaluated based on the total circumstances and verified when necessary.

Prescription Drug Monitoring Programs

A Prescription Drug Monitoring Program (PDMP) is a state-operated electronic database that tracks prescriptions for designated controlled substances.

PDMP information can help healthcare professionals:

The exact medications tracked and rules for checking the database vary by state.

OBRA ’90 and Medicaid Drug Utilization Review

The Omnibus Budget Reconciliation Act of 1990 (OBRA ’90) established important requirements for outpatient prescription drugs provided through Medicaid.

Under federal Medicaid requirements, states must maintain a Drug Utilization Review (DUR) program that includes prospective and retrospective review and supports appropriate medication use.

Prospective Drug Review

Before a Medicaid prescription is dispensed, the medication-use review may evaluate concerns such as:

Patient Counseling

OBRA ’90 also established requirements related to pharmacist counseling for Medicaid beneficiaries, with implementation through state Medicaid programs.

Important distinction: The federal OBRA ’90 counseling requirement was created for Medicaid outpatient prescriptions. It did not itself establish a universal federal counseling mandate covering every patient in the United States.

Many states later adopted broader counseling requirements through their own pharmacy laws and regulations, so pharmacists commonly offer counseling to patients beyond Medicaid beneficiaries.

Maintaining a Patient Medication Profile

Patient profiles support prospective DUR and safe medication use. Depending on applicable requirements and pharmacy procedures, a profile may contain:

  1. Patient’s full name
  2. Address
  3. Telephone number
  4. Date of birth or age
  5. Sex or gender information when clinically relevant and collected
  6. Current and previous medications
  7. Known allergies and adverse drug reactions
  8. Relevant medical conditions
  9. Pharmacist notes or clinical comments
  10. Other information needed to evaluate medication therapy

The patient profile allows pharmacy personnel to identify concerns such as allergies, duplicate therapy, interactions, unusual doses, and adherence problems before medication is dispensed.

Elements to Assure Safe Use

ETASU stands for Elements to Assure Safe Use. ETASU are specific requirements that may be included in a Risk Evaluation and Mitigation Strategy (REMS) when additional safeguards are necessary to ensure that a medication’s benefits outweigh its serious risks.

Depending on the medication, ETASU may require:

Not every REMS includes ETASU. The requirements are tailored to the specific risks of the medication.

RCRA P-, U-, and D-Coded Hazardous Wastes

Under the Resource Conservation and Recovery Act (RCRA), pharmaceutical waste may be considered hazardous because it appears on an EPA hazardous-waste list or because it exhibits a hazardous characteristic.

An important distinction is that P and U wastes are listed hazardous wastes, while D codes identify characteristic hazardous wastes. Therefore, the term “P-, D-, and U-listed medications” is not technically precise.

P-Listed Wastes: Acutely Hazardous Commercial Chemical Products

The P-list includes discarded commercial chemical products that EPA classifies as acute hazardous wastes.

For a discarded chemical to qualify under the P- or U-list, the listed chemical generally must be:

P-listed wastes require particularly careful management because of their acute toxicity.

Examples with pharmaceutical relevance include:

However, whether a particular drug product is P-listed depends on its exact formulation and concentration. For example, warfarin is not automatically P-listed at every concentration.

Important exception: FDA-approved over-the-counter nicotine-replacement therapies, such as certain nicotine patches, gums, and lozenges, are excluded from the federal P075 hazardous-waste listing when discarded under EPA’s hazardous-waste pharmaceutical rule.

U-Listed Wastes: Toxic Commercial Chemical Products

The U-list includes discarded commercial chemical products that are hazardous but are not classified as acutely hazardous in the same way as P-listed wastes.

Examples relevant to healthcare may include:

EPA notes that only about 30 P- and U-listed commercial chemicals have pharmaceutical uses, although many different branded products may contain those listed ingredients. Therefore, it is not accurate to say that there are more than 400 U-listed drugs specifically.

D-Coded Wastes: Hazardous by Characteristic

D codes do not represent a separate list of medications. Instead, they identify wastes that exhibit one or more hazardous characteristics.

EPA recognizes four main hazardous-waste characteristics:

Waste CodeCharacteristicGeneral Description
D001IgnitabilityWaste that can readily catch fire under specified conditions
D002CorrosivityStrongly acidic or alkaline waste, or certain liquids that corrode steel
D003ReactivityUnstable waste capable of dangerous reactions, toxic-gas generation, explosion, or detonation
D004–D043ToxicityWaste containing specified toxic contaminants above regulatory limits

Examples of Characteristic Pharmaceutical Waste

Pharmaceutical waste may receive a D code when it meets the regulatory criteria.

Examples include:

Special Note on Nitroglycerin

Nitroglycerin appears historically as P081, but medicinal nitroglycerin formulations that do not exhibit the D003 reactivity characteristic are not federally regulated as P081 hazardous waste under EPA’s current interpretation. Therefore, medicinal nitroglycerin should not automatically be listed as P-coded pharmaceutical waste.

Handling Containers and Devices

Syringes, vials, or other containers that held a P-listed drug may sometimes remain regulated depending on whether they meet EPA’s definition of an empty container and the circumstances of disposal. It is therefore too broad to state that every device used with a P-listed medication automatically becomes P-listed waste.